Last reviewed · How we verify

Vemurafenib plus Cobimetinib — Competitive Intelligence Brief

Vemurafenib plus Cobimetinib (vemurafenib-plus-cobimetinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Live · refreshed every 30 min

Target snapshot

Vemurafenib plus Cobimetinib (vemurafenib-plus-cobimetinib) — Pfizer Inc.. Vemurafenib and cobimetinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to halt cancer cell growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vemurafenib plus Cobimetinib TARGET vemurafenib-plus-cobimetinib Pfizer Inc. phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vemurafenib plus Cobimetinib — Competitive Intelligence Brief. https://druglandscape.com/ci/vemurafenib-plus-cobimetinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: